Bio-Rad Laboratories, Inc.
corporate_fare Company Profile
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 10 items for BIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-04, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BIO spans 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Bio-Rad to Slash Jobs, Shut Facilities in $80–90M Restructuring Push
- Bio-Rad Q2 Revenue Beats by $27M on Diagnostics Strength, Reaffirms Outlook
- Bio-Rad Tops Q2 Revenue, Launches $80–90M Restructuring, and Reaffirms 2026 Outlook
- Activist Investor Elliott Plans Push to Boost Bio-Rad Stock, Sources Say
- Bio-Rad Reports Steep Q1 Net Loss of $527.1M, EPS Plunges to ($19.55)
Financial Snapshot
Short Interest & Short Volume
3.83 days to coverFINRA reported short interest of 998,654 shares in BIO as of the September 15, 2026 settlement, a 11.6% decrease from the prior period — about 3.8 days to cover at its recent average daily volume. On October 2, 2026, 77.0% of BIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.